Treatment of organ transplant-related lymphoma

First described in organ transplant recipients in 1968, post-transplant lymphoproliferative disorder (PTLD) remains an often devastating complication of immunosuppression. Similar, if not identical, Epstein-Barr virus (EBV)-associated B lymphoproliferations have since been described in congenital and other acquired immunodeficiency states. Although PTLD is often morphologically indistinguishable from aggressive non-Hodgkin's lymphoma, the pathogenesis, presentation, clinical course, and management options differ significantly from those of classic NHL.